Allogeneic Hematopoietic Stem Cell Transplantation
Conditions
Brief summary
Mesenchymal stem cells (MSCs) are known to exhibit immunomodulatory, anti-inflammatory, and pro-angiogenic properties, and therefore have the potential to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) .The study is aimed to identify and evaluate the potential benefits of MSCs infusion during allogeneic HSCT, with regard to the engraftment, graft versus host disease (GVHD), post-transplant relapse and survival.
Interventions
BIOLOGICALCotransplant with MSCs
Co-transplantation of MSCs during allogeneic HSCT
Sponsors
Fujian Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 65 Years
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent * Aged \<65 years * Willing to transplant * Cardiac: Left ventricular ejection fraction ≥ 50% * Adequate renal and hepatic function * Performance status: Karnofsky ≥ 70%
Exclusion criteria
* Pregnant or lactating females. * Any co-morbidity precluding the administration of MSCs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival Rate | up to 2 years after HSCT |
Secondary
| Measure | Time frame |
|---|---|
| Mean Time to Engraftment | Baseline to engraftment, assessed minimally 28 days post transplant |
| Transplant-Related Mortality | up to 1 months after HSCT |
| Cumulative Incidence of Graft-versus Host Disease | up to 2 years after HSCT |
| Incidence of Systemic Infections | up to 2 years after HSCT |
| Rates of Relapse | up to 2 years after HSCT |
Countries
China
Contacts
Primary ContactTing Yang, Prof.
Outcome results
None listed